Ee Lin joined HTANALYSTS in May 2023 and has over 15 years’ experience in the pharmaceutical industry. 

Ee Lin joined HTANALYSTS in May 2023 with over 15 years’ experience in the pharmaceutical industry and a background in clinical pharmacy. She specialises in PBAC and MSAC reimbursement, feasibility assessments and broader health economics and outcomes research.  She has supported PBAC and MSAC reimbursement across multiple therapeutic areas, alongside evidence synthesis and stakeholder engagement.

Prior to joining HTANALYSTS, Ee Lin held senior roles at Pfizer and AbbVie where she specialised in pharmacovigilance, working with various brand teams and stakeholders to manage product safety from the clinical trial phase through to post-marketing. Her experience includes regulatory submissions, product risk management, safety data extraction and analysis and quality systems management. With therapy area expertise including oncology and neurology, Ee Lin also generated patient safety insights to support product launch excellence and the design and execution of Medical and Commercial strategic initiatives. 

Ee Lin is a registered pharmacist and holds a Bachelor of Pharmacy with 1st Class Honours from the University of Sydney and a Master of Public Health in Health Economic Evaluation from the University of New South Wales.